Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Eli Lilly Alzheimer’s Drug Gains FDA Breakthrough Designation

Published 06/24/2021, 07:48 AM
Updated 06/24/2021, 08:09 AM
© Bloomberg. An Eli Lilly & Co. logo is seen on a box of insulin medication in this arranged photograph at a pharmacy in Princeton, Illinois, U.S., on Monday, Oct. 23, 2017. Eli Lilly is scheduled to release earnings figures on October 24. Photographer: Daniel Acker/Bloomberg

© Bloomberg. An Eli Lilly & Co. logo is seen on a box of insulin medication in this arranged photograph at a pharmacy in Princeton, Illinois, U.S., on Monday, Oct. 23, 2017. Eli Lilly is scheduled to release earnings figures on October 24. Photographer: Daniel Acker/Bloomberg

(Bloomberg) -- Eli Lilly & Co (NYSE:LLY) rose after its experimental drug for Alzheimer’s disease gained breakthrough status from U.S. regulators, a designation that will speed its consideration for approval.

Biogen's (NASDAQ:BIIB) Aduhelm was approved for Alzheimer’s on June 7 after gaining breakthrough status in a controversial move by the Food and Drug Administration. Lecanemab, another drug being developed by Biogen and its partner Eisai (OTC:ESALY), received the same designation Wednesday. Lilly gained as much as 8.7% in trading before U.S. markets opened. Biogen fell 3.5%.

Like Aduhelm, Lilly’s donanemab attacks amyloid, an abnormal protein believed to be involved in the damage Alzheimer’s causes in the brain. Critics of the Biogen drug’s approval have said that human trials haven’t definitively shown its effectiveness, and that its $56,000 annual price tag is excessive.

Lilly intends to submit a biologics license application for donanemab under the accelerated approval pathway later this year, according to a company statement Thursday.

Breakthrough therapy status is designed to speed development and review of drugs for serious or life threatening ailments. It doesn’t mean the FDA will approve the drug in question, or that the agency has already determined that the experimental medicine is, in fact, a breakthrough.

©2021 Bloomberg L.P.

© Bloomberg. An Eli Lilly & Co. logo is seen on a box of insulin medication in this arranged photograph at a pharmacy in Princeton, Illinois, U.S., on Monday, Oct. 23, 2017. Eli Lilly is scheduled to release earnings figures on October 24. Photographer: Daniel Acker/Bloomberg

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.